The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 24, 2015

Filed:

Sep. 30, 2011
Applicants:

Takeshi Kuwada, Toshima-ku, JP;

Mitsukane Yoshinaga, Toshima-ku, JP;

Tomoko Ishizaka, Toshima-ku, JP;

Daisuke Wakasugi, Toshima-ku, JP;

Shin-ichi Shirokawa, Toshima-ku, JP;

Nobutaka Hattori, Toshima-ku, JP;

Youichi Shimazaki, Toshima-ku, JP;

Naoki Miyakoshi, Toshima-ku, JP;

Inventors:

Takeshi Kuwada, Toshima-ku, JP;

Mitsukane Yoshinaga, Toshima-ku, JP;

Tomoko Ishizaka, Toshima-ku, JP;

Daisuke Wakasugi, Toshima-ku, JP;

Shin-ichi Shirokawa, Toshima-ku, JP;

Nobutaka Hattori, Toshima-ku, JP;

Youichi Shimazaki, Toshima-ku, JP;

Naoki Miyakoshi, Toshima-ku, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 265/30 (2006.01); C07D 249/12 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 403/10 (2006.01); C07D 405/10 (2006.01); C07D 405/12 (2006.01); C07D 413/10 (2006.01); C07D 413/14 (2006.01); C07D 451/06 (2006.01); C07D 491/08 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01);
U.S. Cl.
CPC ...
C07D 249/12 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 403/10 (2013.01); C07D 405/10 (2013.01); C07D 405/12 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 451/06 (2013.01); C07D 491/08 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01);
Abstract

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.


Find Patent Forward Citations

Loading…